
[Glu1]-Fibrinopeptide B
CAS No. 103213-49-6
[Glu1]-Fibrinopeptide B( —— )
Catalog No. M30562 CAS No. 103213-49-6
[Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 640 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product Name[Glu1]-Fibrinopeptide B
-
NoteResearch use only, not for human use.
-
Brief Description[Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts.
-
Description[Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts. (In Vitro):hFpB causes directed cell migration of PMN and fibroblasts that is optimal at approximately 10 nM. hFpB causes a rapid, dose-dependent increase in PMN cytoskeletal associated actin, but unlike fMLP, hFpB does not cause PMN aggregation, release of lysosomal enzymes (lysozyme and beta-glucuronidase), or the production of superoxide anion. These results suggest that hFpB may have a role in recruiting PMN and fibroblasts at sites of fibrin deposition and turnover. The capacity of hFpB to cause PMN chemotaxis without causing concurrent release of lysosomal enzymes or the production of superoxide anion is further evidence for the complexity of PMN responses to chemotactic agents.
-
In VitrohFpB causes directed cell migration of PMN and fibroblasts that is optimal at approximately 10 nM. hFpB causes a rapid, dose-dependent increase in PMN cytoskeletal associated actin, but unlike fMLP, hFpB does not cause PMN aggregation, release of lysosomal enzymes (lysozyme and beta-glucuronidase), or the production of superoxide anion. These results suggest that hFpB may have a role in recruiting PMN and fibroblasts at sites of fibrin deposition and turnover. The capacity of hFpB to cause PMN chemotaxis without causing concurrent release of lysosomal enzymes or the production of superoxide anion is further evidence for the complexity of PMN responses to chemotactic agents.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number103213-49-6
-
Formula Weight1570.6
-
Molecular FormulaC66H95N19O26
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:Glu-Gly-Val-Asn-Asp-Asn-Glu-Glu-Gly-Phe-Phe-Ser-Ala-Arg
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Senior RM, et al. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest. 1986 Mar;77(3):1014-9.
molnova catalog



related products
-
T3Inh-1
T3Inh-1 is an effective and selective inhibitor of ppGalNAc-T3 with an IC50 of 7 μM. T3Inh-1 prevents breast cancer cells. T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects.
-
Xenalipin
Xenalipin has hypolipidemic. It reduces blood cholesterol and triglycerides in rats.
-
(+)-alpha-Pinene
(1R)-α-Pinene is a natural product for research related to life sciences.